{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:17:34Z","timestamp":1790572654479,"version":"4.1.0"},"reference-count":68,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2002,5,15]],"date-time":"2002-05-15T00:00:00Z","timestamp":1021420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Virol"],"published-print":{"date-parts":[[2002,5,15]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>To identify cell proteins regulated by the Epstein-Barr virus (EBV) transcription factor EBNA-2, we analyzed a cell line with conditional EBNA-2 activity by using microarray expression profiling. This led to the identification of two novel target genes induced by EBNA-2. The first of these, interleukin-16, is an immunomodulatory cytokine involved in the regulation of CD4 T cells. The second, AML-2, is a member of the Runt domain family of transcription factors. Quiescent B cells initially expressed AML-1 but, 48 h after virus infection, the levels of AML-1 decreased dramatically, whereas the amount of AML-2 protein increased. Analysis of a panel of B-cell lines indicated that AML-2 expression is normally predominant in EBV latency III, whereas AML-1 is associated with EBV latency I or EBV-negative cells. The AML genes are the first example of cell transcription factors whose expression correlates with the latency I\/III phenotype.<\/jats:p>","DOI":"10.1128\/jvi.76.10.4919-4927.2002","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T10:09:29Z","timestamp":1027764569000},"page":"4919-4927","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":70,"title":["Expression of Transcription Factor AML-2 (RUNX3, CBF\u03b1-3) Is Induced by Epstein-Barr Virus EBNA-2 and Correlates with the B-Cell Activation Phenotype"],"prefix":"10.1128","volume":"76","author":[{"given":"Lindsay C.","family":"Spender","sequence":"first","affiliation":[{"name":"Ludwig Institute for Cancer Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina H.","family":"Cornish","sequence":"additional","affiliation":[{"name":"Ludwig Institute for Cancer Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Ludwig Institute for Cancer Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Farrell","sequence":"additional","affiliation":[{"name":"Ludwig Institute for Cancer Research"},{"name":"Virology and Cell Biology Section, Imperial College Faculty of Medicine, London W2 1PG, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.10.5273"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910190105"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1201704"},{"key":"e_1_3_2_5_2","first-page":"1413","volume":"13","year":"1996","unstructured":"Cannell, E., P. Farrell, and A. Sinclair. 1996. Epstein-Barr virus exploits the normal cell pathway to regulate Rb activity during the immortalisation of primary B cells. Oncogene 13 : 1413-1421.","journal-title":"Oncogene"},{"key":"e_1_3_2_6_2","first-page":"186","volume":"26","year":"2000","unstructured":"Chimienti, G., M. Alaibac, F. Marzullo, A. Carbone, and G. Pepe. 2000. The expression pattern of the AML1 gene in non-Hodgkin's B-cell lymphomas and normal B lymphocytes. Blood Cell Mol. Dis. 26 : 186-192.","journal-title":"Dis."},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.4049\/jimmunol.161.6.3114","volume":"161","year":"1998","unstructured":"Chupp, G. L., E. A. Wright, D. Wu, M. Vallen-Mashikian, W. W. Cruikshank, D. M. Center, H. Kornfeld, and J. S. Berman. 1998. Tissue and T-cell distribution of precursor and mature IL-16. J. Immunol. 161 : 3114-3119.","journal-title":"J. Immunol."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.23.9558"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.4049\/jimmunol.157.12.5240","volume":"157","year":"1996","unstructured":"Cruikshank, W. W., K. Lim, A. C. Theodore, J. Cook, G. Fine, P. F. Weller, and D. M. Center. 1996. IL-16 inhibition of CD3-dependent lymphocyte activation and proliferation. J. Immunol. 157 : 5240-5248.","journal-title":"J. Immunol."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/35104560"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.18.3.1322"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.5.1935"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.11.4917"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.6.4.1050-1057.1986"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.4049\/jimmunol.139.1.313","volume":"139","year":"1987","unstructured":"Gregory, C. D., T. Tursz, C. F. Edwards, C. Tetaud, M. Talbot, B. Caillou, A. B. Rickinson, and M. Lipinski. 1987. Identification of a subset of normal B cells with a Burkitt's lymphoma (BL)-like phenotype. J. Immunol. 139 : 313-318.","journal-title":"J. Immunol."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.44.31577"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.71.9.6611-6618.1997"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.8016657"},{"key":"e_1_3_2_19_2","first-page":"4784","volume":"55","year":"1995","unstructured":"Hollyoake, M., A. Stuhler, P. Farrell, J. Gordon, and A. Sinclair. 1995. The normal cell cycle activation program is exploited during the infection of quiescent B lymphocytes by Epstein-Barr virus. Cancer Res. 55 : 4784-4787.","journal-title":"Cancer Res."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1996.tb00367.x"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.69.1.253-262.1995"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.73.5.4481-4484.1999"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.5.2474"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1995.tb06978.x"},{"key":"e_1_3_2_25_2","first-page":"2511","year":"2001","unstructured":"Kieff, E., and A. Rickinson. 2001. Epstein-Barr virus and its replication, p. 2511-2573. In D. M. Knipe and P. M. Howley (ed.), Fields virology, 4th ed. Lippincott, Philadelphia, Pa.","journal-title":"Fields virology"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1006\/viro.1996.0518"},{"key":"e_1_3_2_27_2","first-page":"883","volume":"12","year":"1996","unstructured":"Kurokawa, M., T. Tanaka, K. Tanaka, S. Ogawa, K. Mitani, Y. Yazaki, and H. Hirai. 1996. Overexpression of the AML1 proto-oncoprotein in NIH 3T3 cells leads to neoplastic transformation depending on the DNA-binding and transactivational potencies. Oncogene 12 : 883-892.","journal-title":"Oncogene"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1994.tb06900.x"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.31.21651"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.20.11590"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1006\/geno.1994.1519"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.35.24671"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.68.9.5375-5383.1994"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.55.3.710-720.1985"},{"key":"e_1_3_2_35_2","first-page":"303","volume":"13","year":"1996","unstructured":"Meyers, S., N. Lenny, W. Sun, and S. W. Hiebert. 1996. AML-2 is a potential target for transcriptional regulation by the t(8;21) and t(12;21) fusion proteins in acute leukemia. Oncogene 13 : 303-312.","journal-title":"Oncogene"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1993.tb05933.x"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1990.tb02540.x"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.8.3740-3752.2001"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.71.9.6619-6628.1997"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.20.9934"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.44.3.834-844.1982"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.61.5.1310-1317.1987"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.12.3662.bloodjournal85123662"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1987.tb02568.x"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.7.3806"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2567.2000.00959.x"},{"key":"e_1_3_2_47_2","doi-asserted-by":"crossref","first-page":"6751","DOI":"10.4049\/jimmunol.161.12.6751","volume":"161","year":"1998","unstructured":"Shi, M. J., and J. Stavnezer. 1998. CBF \u03b13 (AML2) is induced by TGF-\u03b21 to bind and activate the mouse germline Ig \u03b1 promoter. J. Immunol. 161 : 6751-6760.","journal-title":"J. Immunol."},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1994.tb06634.x"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.2.1365-1376.1998"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.73.6.4678-4688.1999"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.8.3537-3546.2001"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(01)00210-2"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.2.607.bloodjournal862607"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.16.7.3967"},{"key":"e_1_3_2_55_2","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.4049\/jimmunol.157.5.1958","volume":"157","year":"1996","unstructured":"Theodore, A. C., D. M. Center, J. Nicoll, G. Fine, H. Kornfeld, and W. W. Cruikshank. 1996. CD4 ligand IL-16 inhibits the mixed lymphocyte reaction. J. Immunol. 157 : 1958-1964.","journal-title":"J. Immunol."},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.8.3259"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.15.9.4735"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.69.1.585-588.1995"},{"key":"e_1_3_2_59_2","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.4049\/jimmunol.158.5.2251","volume":"158","year":"1997","unstructured":"Uchida, H., J. Zhang, and S. D. Nimer. 1997. AML1A and AML1B can transactivate the human IL-3 promoter. J. Immunol. 158 : 2251-2258.","journal-title":"J. Immunol."},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1994.tb06901.x"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.1.430"},{"key":"e_1_3_2_62_2","first-page":"51","volume":"1999","year":"1999","unstructured":"Westendorf, J. J., and S. W. Hiebert. 1999. Mammalian Runt-domain proteins and their roles in hematopoiesis, osteogenesis, and leukemia. J. Cell Biochem. 1999(Suppl. 32-33): 51-58.","journal-title":"J. Cell Biochem."},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.70.9.6020-6028.1996"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.19.8893-8903.2000"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.14.12.8085-8095.1994"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.2.1144"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M001526200"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1996.tb01098.x"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1993.tb05642.x"}],"container-title":["Journal of Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JVI.76.10.4919-4927.2002","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JVI.76.10.4919-4927.2002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,23]],"date-time":"2023-04-23T16:03:42Z","timestamp":1682265822000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/JVI.76.10.4919-4927.2002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,5,15]]},"references-count":68,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2002,5,15]]}},"alternative-id":["10.1128\/JVI.76.10.4919-4927.2002"],"URL":"https:\/\/doi.org\/10.1128\/jvi.76.10.4919-4927.2002","relation":{},"ISSN":["0022-538X","1098-5514"],"issn-type":[{"value":"0022-538X","type":"print"},{"value":"1098-5514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,5,15]]},"assertion":[{"value":"2001-11-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2002-02-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2002-05-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}